AKT1 and cancer: Based on the aforementioned results, both the putative targets and key targets of KXYA are enriched in pathways in cancer, hepatitis B, viral carcinogenesis, focal adhesion, microRNAs in cancer, proteoglycans in cancer, and PI3K-Akt signaling.